204 related articles for article (PubMed ID: 25275045)
21. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
24. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
25. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
26. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.
Krauth MT; Böhm A; Agis H; Sonneck K; Samorapoompichit P; Florian S; Sotlar K; Valent P
Exp Hematol; 2007 Jan; 35(1):108-16. PubMed ID: 17198879
[TBL] [Abstract][Full Text] [Related]
27. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
van Der Velden VH; te Marvelde JG; Hoogeveen PG; Bernstein ID; Houtsmuller AB; Berger MS; van Dongen JJ
Blood; 2001 May; 97(10):3197-204. PubMed ID: 11342449
[TBL] [Abstract][Full Text] [Related]
28. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin.
Matsumoto T; Jimi S; Hara S; Takamatsu Y; Suzumiya J; Tamura K
Leuk Lymphoma; 2012 Jul; 53(7):1399-405. PubMed ID: 22242821
[TBL] [Abstract][Full Text] [Related]
29. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
[TBL] [Abstract][Full Text] [Related]
30. Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.
Jawad M; Yu N; Seedhouse C; Tandon K; Russell NH; Pallis M
BMC Cancer; 2012 Sep; 12():431. PubMed ID: 23013471
[TBL] [Abstract][Full Text] [Related]
31. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
32. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
34. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
[TBL] [Abstract][Full Text] [Related]
35. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Gbadamosi M; Meshinchi S; Lamba JK
Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
[TBL] [Abstract][Full Text] [Related]
36. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
37. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
Voutsadakis IA
Anticancer Drugs; 2002 Aug; 13(7):685-92. PubMed ID: 12187324
[TBL] [Abstract][Full Text] [Related]
38. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Giles F; Estey E; O'Brien S
Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
[TBL] [Abstract][Full Text] [Related]
39. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
40. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.
Khan N; Hills RK; Virgo P; Couzens S; Clark N; Gilkes A; Richardson P; Knapper S; Grimwade D; Russell NH; Burnett AK; Freeman SD
Leukemia; 2017 May; 31(5):1059-1068. PubMed ID: 27795558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
